Targeted therapy and elderly people: A review

被引：28

作者：

Daste, Amaury ^{[1
,2
]}

Chakiba, Camille ^{[2
,3
]}

Domblides, Charlotte ^{[1
]}

Gross-goupil, Marine ^{[1
]}

Quivy, Amandine ^{[1
]}

Ravaud, Alain ^{[1
,2
]}

Soubeyran, Pierre ^{[2
,3
]}

机构：

[1] CHU Bordeaux, Dept Med Oncol, Hop St Andre, Bordeaux Univ Hospital, 1 Rue Jean Burguet, F-33000 Bordeaux, France

[2] Univ Bordeaux, Bordeaux, France

[3] Inst Bergonie, Dept Med Oncol, Bordeaux, France

来源：

EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷

关键词：

Targeted therapy; Elderly people; Adverse events; CELL-LUNG-CANCER; METASTATIC BREAST-CANCER; FACTOR RECEPTOR MUTATIONS; PHASE-III TRIAL; OLDER PATIENTS; OPEN-LABEL; DOUBLE-BLIND; 1ST-LINE TREATMENT; ADJUVANT CHEMOTHERAPY; PLUS CAPECITABINE;

D O I：

10.1016/j.ejca.2016.10.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of targeted therapy (TT) has radically changed the outcome of various cancers and introduces the era of personalised medicine. Elderly patients (>= 65 years) represent the majority of cancer diagnoses and deaths by age group with an increase expected over the next decade. This group of patients is heterogeneous with three categories of patients: fit, vulnerable and frail, with specific treatment for each subgroup. In this review, we assess safety and efficacy of TT in elderly patients, principally from data of pivotal clinical trials with subgroup analysis, but elderly people represented a small percentage of the total number of patients. Few specific trials have been carried out for TT in elderly people with most patients considered to be fit. However, tolerance and efficacy of TT in elderly patients seems similar to that for younger patients, with an increase in incidence of specific adverse events in elderly patients for selected TTs. An adapted geriatric selection and strict monitoring could help to decrease toxicity, and specific clinical trials for elderly cancer patients would be useful. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：199 / 215

页数：17

共 115 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2]

[Anonymous], 1999, SEER1 CANC STAT REV

[3] Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study [J].

Asami, Kazuhiro ;

Koizumi, Tomonobu ;

Hirai, Kazuya ;

Ameshima, Shingo ;

Tsukadaira, Akihiro ;

Morozumi, Nobutoshi ;

Morikawa, Akio ;

Atagi, Shinji ;

Kawahara, Masaaki .

CLINICAL LUNG CANCER, 2011, 12 (06) :387-392

[4]

Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224

[5] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[6] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[7] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[8] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[9] Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study [J].

Bonnefoi, H. ;

Jacot, W. ;

Saghatchian, M. ;

Moldovan, C. ;

Venat-Bouvet, L. ;

Zaman, K. ;

Matos, E. ;

Petit, T. ;

Bodmer, A. ;

Quenel-Tueux, N. ;

Chakiba, C. ;

Vuylsteke, P. ;

Jerusalem, G. ;

Brain, E. ;

Tredan, O. ;

Messina, C. G. M. ;

Slaets, L. ;

Cameron, D. .

ANNALS OF ONCOLOGY, 2015, 26 (02) :325-332

[10] Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study [J].

Brunello, A. ;

Basso, U. ;

Sacco, C. ;

Sava, T. ;

De Vivo, R. ;

Camerini, A. ;

Barile, C. ;

Roma, A. ;

Maruzzo, M. ;

Falci, C. ;

Zagonel, V. .

ANNALS OF ONCOLOGY, 2013, 24 (02) :336-342

← 1 2 3 4 5 6 7 8 9 10 →